Sinphar Pharmaceutical Co Ltd (1734) – Strategy, SWOT and Corporate Finance Report

Sinphar Pharmaceutical Co Ltd (1734) – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company

Key Highlights

Sinphar Pharmaceutical Co Ltd (Sinphar) is a healthcare company which carries out the development, manufacture and sale of pharmaceutical drugs, healthy foods and cosmetics. The company’s pharmaceutical product portfolio includes antifungal agents, anti-hypersensitive agents, cardiovascular agents, dermatologic agents, ophthalmic agents, skincare products, health supplements among others. It also has several products in pipeline addressing dementia, dry age related macular degeneration, triple-negative breast cancer, pancreatic cancer, genital warts and others. Sinphar offers contract manufacturing services to pharmaceutical companies for the development of new products. It has presence in China, Taiwan, Canada, and other countries. Sinphar is headquartered in Tungshan, Yilan, Taiwan.

Scope

• Detailed information on Sinphar Pharmaceutical Co Ltd required for business and competitor intelligence needs

• A study of the major internal and external factors affecting Sinphar Pharmaceutical Co Ltd in the form of a SWOT analysis

• An in-depth view of the business model of Sinphar Pharmaceutical Co Ltd including a breakdown and examination of key business segments

• News about Sinphar Pharmaceutical Co Ltd, such as business expansion, restructuring, and contract wins

• Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

• Gain understanding of Sinphar Pharmaceutical Co Ltd and the factors that influence its strategies.

• Track strategic initiatives of the company and latest corporate news and actions.

• Assess Sinphar Pharmaceutical Co Ltd as a prospective partner, vendor or supplier.

• Support sales activities by understanding your customers' businesses better.

• Stay up to date on Sinphar Pharmaceutical Co Ltds business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Taiwan Biotech Co Ltd

Sunty Development Co Ltd

ScinoPharm Taiwan Ltd

DURECT Corp

Abnova Corp

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Sinphar Pharmaceutical Co Ltd - Key Facts

Sinphar Pharmaceutical Co Ltd - Key Employees

Sinphar Pharmaceutical Co Ltd - Key Employee Biographies

Sinphar Pharmaceutical Co Ltd - Major Products and Services

Sinphar Pharmaceutical Co Ltd - History

Sinphar Pharmaceutical Co Ltd - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 – Company Analysis

Company Overview

Sinphar Pharmaceutical Co Ltd - Business Description

R&D Overview

Sinphar Pharmaceutical Co Ltd - SWOT Analysis

SWOT Analysis - Overview

Sinphar Pharmaceutical Co Ltd - Strengths

Sinphar Pharmaceutical Co Ltd - Weaknesses

Sinphar Pharmaceutical Co Ltd - Opportunities

Sinphar Pharmaceutical Co Ltd - Threats

Sinphar Pharmaceutical Co Ltd - Key Competitors

Section 3 – Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances

Sinphar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023

Sinphar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023

Sinphar Pharmaceutical Co Ltd, Recent Deals Summary

Section 5 – Company’s Recent Developments

Dec 23, 2022: Guarding People’s Health Xinghui Pharmaceutical Group Has Sufficient Supply of Analgesic and Antipyretic Drugs

Aug 18, 2022: Xinghui Pharmaceutical Group Is Developing Steadily, With Both Revenue and Profit Reaching New Highs in the Same Period in Recent Years

Jul 27, 2022: 2022 Biotechnology Exhibition - Xinghui Provides Multiple Channels for Comprehensive Health Management After the Epidemic

Jul 13, 2022: Xing Huirong Won the Double Affirmation of the Gold Award and the Special Award of the Japan Design, Creativity and Invention Exhibition

May 17, 2022: Xinghuirong’s Anti-aging Active Ingredient Has Won Three International Awards in a Row and Joined Hands With Its Subsidiary Xinghui Tianli to Leap Onto the International Stage

Section 6 – Appendix

Methodology

Ratio Definitions

About MarketLine

Contact Us

Disclaimer

List of Tables

List of Tables

Sinphar Pharmaceutical Co Ltd, Key Facts

Sinphar Pharmaceutical Co Ltd, Key Employees

Sinphar Pharmaceutical Co Ltd, Key Employee Biographies

Sinphar Pharmaceutical Co Ltd, Major Products and Services

Sinphar Pharmaceutical Co Ltd, History

Sinphar Pharmaceutical Co Ltd, Subsidiaries

Sinphar Pharmaceutical Co Ltd, Key Competitors

Sinphar Pharmaceutical Co Ltd, Ratios based on current share price

Sinphar Pharmaceutical Co Ltd, Annual Ratios

Sinphar Pharmaceutical Co Ltd, Annual Ratios (Cont…1)

Sinphar Pharmaceutical Co Ltd, Annual Ratios (Cont…2)

Sinphar Pharmaceutical Co Ltd, Interim Ratios

Sinphar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023

Sinphar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023

Sinphar Pharmaceutical Co Ltd, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

List of Figures

Sinphar Pharmaceutical Co Ltd, Performance Chart (2018 – 2022)

Sinphar Pharmaceutical Co Ltd, Ratio Charts

Sinphar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023

Sinphar Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

    Pricing

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports